SCHEMBL13725919

SCHEMBL13725919

C=Cc1ccc(OC)c(OCc2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 1/20 0.60
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.56
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
APP P05067 4/20 0.53
HPGD P15428 2/20 0.53
HTT P42858 1/20 0.53
POLB P06746 1/20 0.52
UBE2N P61088 1/20 0.52
SMPD1 P17405 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 1/20 0.52
PDCD1 Q15116 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
PDE4A P27815 1/20 0.51
PDE4B Q07343 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30341701 0.94 APP (0.60) ALDH1A1KMT2AMEN1APPHPGD
SCHEMBL348043 0.94 APP (0.60) ALDH1A1KMT2AMEN1APPHPGD
SCHEMBL6546267 0.91 POLB (0.57) AMY1AALDH1A1LMNAKMT2AAPP
SCHEMBL9587052 0.88 CYP1A1 (0.65) AMY1AALDH1A1LMNAAPPHPGD
SCHEMBL9587050 0.88 CYP1A1 (0.65) AMY1AALDH1A1LMNAAPPHPGD
SCHEMBL9861768 0.86 SMN1; SMN2 (0.58) ALDH1A1LMNAKMT2AMEN1APP
SCHEMBL752160 0.85 ALDH1A1 (0.65) AMY1AALDH1A1LMNAKMT2AMEN1
SCHEMBL20058837 0.85 AMY1A (0.60) AMY1AALDH1A1LMNAKMT2AMEN1
SCHEMBL29377794 0.85 ALDH1A1 (0.65) AMY1AALDH1A1LMNAKMT2AMEN1
SCHEMBL15963939 0.84 APP (0.58) AMY1AALDH1A1LMNAAPPHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104761537-A Preparation method of beta-chloro-1,3-dithiane derivative UNIV LANZHOU 2015-07-08 CN claimed
US-11634375-B2 Prenylated hydroxystilbenes Kynan Duke IP, LLC (US) 2023-04-25 US disclosed
US-20220380285-A1 PRENYLATED HYDROXYSTILBENES Kynan Duke IP, LLC (US) 2022-12-01 US disclosed
US-11352310-B2 Prenylated hydroxystilbenes Kynan Duke IP, LLC (US) 2022-06-07 US disclosed
US-20200331833-A1 PRENYLATED HYDROXYSTILBENES THE UNIVERSITY OF SYDNEY (AU) 2020-10-22 US disclosed
US-10696615-B2 Prenylated hydroxystilbenes THE UNIVERSITY OF SYDNEY (AU) 2020-06-30 US disclosed
US-20190194105-A1 PRENYLATED HYDROXYSTILBENES THE UNIVERSITY OF SYDNEY (AU) 2019-06-27 US disclosed
US-10196335-B2 Prenylated hydroxystilbenes THE UNIVERSITY OF SYDNEY (AU) 2019-02-05 US disclosed
CN-104761537-B Preparation method of beta-chloro-1,3-dithiane derivative 兰州大学 2017-02-15 CN disclosed
US-20150307429-A1 PRENYLATED HYDROXYSTILBENES Kynan Duke IP, LLC 2015-10-29 US disclosed
CN-104761537-A Preparation method of beta-chloro-1,3-dithiane derivative UNIV LANZHOU 2015-07-08 CN disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
EP-2709975-A1 PRENYLATED HYDROXYSTILBENES THE UNIVERSITY OF SYDNEY (AU) 2014-03-26 EP disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
WO-2012149608-A1 PRENYLATED HYDROXYSTILBENES THE UNIVERSITY OF SIDNEY (AU) 2012-11-08 WO disclosed
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-15 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196335-B2 Prenylated hydroxystilbenes HMGB2, CYP51A1, CYP8B1 AMY1A 4533/4885ALDH1A1 1145/4885LMNA 1076/4885
US-20200331833-A1 PRENYLATED HYDROXYSTILBENES HSD11B1, HSD3B1, CYP8B1 AMY1A 1021/4885ALDH1A1 314/4885LMNA 114/4885
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 AMY1A 4071/4885ALDH1A1 451/4885LMNA 2459/4885
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, KCNB2, SCNN1B AMY1A 4770/4885ALDH1A1 2656/4885LMNA 611/4885
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells CCR3, CCR1, CCR4 AMY1A 3445/4885ALDH1A1 486/4885LMNA 4010/4885
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, SCNN1B, TRPV1 AMY1A 4719/4885ALDH1A1 2495/4885LMNA 816/4885
US-20220380285-A1 PRENYLATED HYDROXYSTILBENES HSD11B1, HSD3B1, CYP8B1 AMY1A 1021/4885ALDH1A1 314/4885LMNA 114/4885
US-20150307429-A1 PRENYLATED HYDROXYSTILBENES HMGB2, CYP51A1, CYP8B1 AMY1A 4533/4885ALDH1A1 1145/4885LMNA 1076/4885
US-10696615-B2 Prenylated hydroxystilbenes HSD11B1, CYP8B1, NR1H2 AMY1A 535/4885ALDH1A1 145/4885LMNA 167/4885
US-11352310-B2 Prenylated hydroxystilbenes HSD11B1, HSD3B1, CYP8B1 AMY1A 1021/4885ALDH1A1 314/4885LMNA 114/4885
US-20190194105-A1 PRENYLATED HYDROXYSTILBENES HSD11B1, CYP8B1, NR1H2 AMY1A 535/4885ALDH1A1 145/4885LMNA 167/4885
US-11634375-B2 Prenylated hydroxystilbenes HCLS1, IWS1, UTS2R AMY1A 3927/4885ALDH1A1 513/4885LMNA 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.